Influence of drugs on arteriovenous vascular access dysfunction
J Vasc Access 2015; 16(Suppl. 9): 61 - 65
Article Type: ORIGINAL ARTICLE
DOI:10.5301/jva.5000365
Authors
Timmy Lee, Charmaine E. Lok
Corresponding author
- Charmaine E. Lok
- 8N-844
- 200 Elizabeth St
- Toronto ON M5G 2C4, Canada
- Charmaine.lok@uhn.ca
Abstract
Vascular access dysfunction, due to venous stenosis at the vein-artery anastomosis in arteriovenous fistulas and vein-graft anastomosis in synthetic arteriovenous grafts, is a major cause of morbidity and mortality in dialysis patients. The two overarching approaches to prevent and treat vascular access dysfunction are from systemic or local (including endovascular and perivascular) routes. However, there are currently very few effective therapies to treat vascular access dysfunction. This article will review major studies evaluating systemic, endovascular, and perivascular therapies for vascular access dysfunction. Ongoing research to evaluate novel innovations to prevent and/or manage vascular access dysfunction appears promising.
Article History
- • Accepted on 04/01/2015
- • Available online on 08/03/2015
- • Published in print on 09/03/2015
Disclosures
This article is available as full text PDF.
Authors
- Lee, Timmy [PubMed] [Google Scholar] 1, 2
- Lok, Charmaine E. [PubMed] [Google Scholar] 3, 4, * Corresponding Author (Charmaine.lok@uhn.ca)
Affiliations
- Department of Medicine and Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama - USA
- Veterans Affairs Medical Center, Birmingham, Alabama - USA
- Division of Nephrology, Department of Medicine, University Health Network, Toronto, Ontario - Canada
- University of Toronto, Toronto, Ontario - Canada
Article usage statistics
The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.